Halozyme Therapeutics Inc (HALO)
Current ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 746,424 | 739,013 | 926,287 | 554,764 | 543,436 |
| Total current liabilities | US$ in thousands | 112,494 | 130,789 | 117,147 | 421,385 | 85,637 |
| Current ratio | 6.64 | 5.65 | 7.91 | 1.32 | 6.35 |
December 31, 2023 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $746,424K ÷ $112,494K
= 6.64
The current ratio of Halozyme Therapeutics Inc. has shown fluctuations over the past five years. As of December 31, 2023, the current ratio stands at a healthy 6.64, indicating that the company has $6.64 in current assets for every dollar of current liabilities. This represents a significant increase compared to the prior year's ratio of 5.65.
In 2021, the company exhibited a notably high current ratio of 7.91, implying a strong liquidity position where it had $7.91 in current assets for each dollar of current liabilities. On the contrary, in 2020, the current ratio dropped substantially to 1.32, suggesting potential liquidity concerns as the company had only $1.32 in current assets for every dollar of current liabilities.
The current ratio rebounded in 2019 to 6.35, showing a favorable liquidity position, similar to the current ratio observed in 2023. Overall, the current ratio trend of Halozyme Therapeutics Inc. reflects varying levels of liquidity and ability to meet short-term obligations over the years, with a notable improvement in 2023.
Peer comparison
Dec 31, 2023